Ashkan Shoamanesh: OCEANIC-STROKE Focus on Stroke Subtypes and Response to Asundexian at ISC26
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”It was a pleasure to discuss the results of our secondary analyses of the OCEANIC-STROKE trial focused on qualifying ischemic stroke subtype and response to asundexian with Video Journal of Neurology (VJNeurology) at ISC26.
Our results demonstrate consistency in the treatment effect of asundexian irrespective of underlying etiology, including robust reductions in ischemic stroke in patients with qualifying stroke due to small vessel occlusive disease (HR 0.61, 95%CI 0.46-0.81) and embolic stroke of undetermined source (HR 0.53, 95%CI 0.37-0.78), without excess in major bleeding or intracranial hemorrhage!
Eagerly awaiting approval of asundexian for the betterment of stroke prevention in our patients with non-cardioembolic ischemic stroke or high-risk TIA.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C